With a market cap of nearly $16 billion, the generic drugmaker Viatris ( VTRS -0.44% ) is minuscule in comparison to the profitable pharma titan AbbVie 's ( ABBV -0.21% ) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unprofitable may not deter investors.